CTRI/2022/03/041155招募中2 期
Phase II randomized controlled trial in patients with metastatic solid cancers to test the efficacy of Olanzapine in improving quality of life.
ational cancer Institute AIIMS0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Cytologically/pathologically confirmed solid cancers ( lung and Gastrointestinal cancers) with recurrent/unresectable/metastatic disease. ECOG Performance status zero to three.
- •With adequate organ and bone marrow function.
- •On palliative chemotherapy
- •Palliative radiotherapy allowed
- •Ability to understand and sign informed consent
排除标准
- •Lactating and pregnant woman
- •Not able to take pills orally and dependent on tube feeding (oral mucositis/candidiasis or dysphagia as determined by clinical examination).
- •Gastric outlet obstruction or Intestinal obstruction. known history of central nervous system disease (e.g., brain metastases, seizure disorder or psychiatric illness) or treatment with another atypical antipsychotic agent such as risperidone, quetiapine, clozapine, phenothiazine, or butyrophenone for thirty days prior to or during protocol therapy. Uncontrolled diabetes mellitus. Use of systemic corticosteroids (prednisolone 5mg or equivalent for more than
- •7 days in the previous 4 weeks)
- •Ascites at time of enrolment.
研究者
相似试验
已完成
2 期
Continued use of Atorvostatin in sepsisSepsis / infection in patients taking statin therapyBlood - Studies of infection and infectious agentsACTRN12605000756628Dr Peter Kruger, Intensive Care Specialist, Princess Alexandra Hospital, Brisbane200
招募中
2 期
Phase II randomised controlled trial of patient-specific adaptive versus continuous Abiraterone or eNZalutamide in metastatic castration-resistant prostate cancer: the ANZadapt studyprostate carcinoma10038597prostate cancerNL-OMON56330eids Universitair Medisch Centrum84
招募中
1 期
Expression-linked and R-ISS-adapted stratification for first line therapy in multiple myeloma patients (ELIAS)MedDRA version: 21.0Level: LLTClassification code: 10028228Term: Multiple myeloma Class: 10029104Multiple MyelomaCTIS2022-500453-16-00niversity Medical Centre Schleswig-Holstein100
招募中
2 期
A Randomized Controlled Phase II Clinical Trial with Intradermal IMO-2125 (Tilsotolimod) in pT3-4 cN0M0 Melanomaskin cancerMelanomaNL-OMON52549Vrije Universiteit Medisch Centrum214
尚未招募
不适用
A clinical trial to investigate immunotherapy (IMO-2125) in the skin of patients with a melanoma which is at least 2 millimeters thickNL-OMON26696VU University medical center214